<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00538811</url>
  </required_header>
  <id_info>
    <org_study_id>648-Med</org_study_id>
    <nct_id>NCT00538811</nct_id>
  </id_info>
  <brief_title>Interferon-gamma With Interferon Alpha and Ribavirin for Hepatitis C Non-responders</brief_title>
  <official_title>Interferon-gamma With Interferon Alpha and Ribavirin for Hepatitis C Patients Who Are Non-responders to Interferon Alpha Plus Ribavirin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aga Khan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aga Khan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      When administered simultaneously, interferon-alpha 2b + interferon-gamma result in dramatic&#xD;
      antiviral synergy.Ribavirin has shown to enhance interferon-gamma levels in patients with&#xD;
      chronic hepatitis C treated with interferon-alpha. Enhancement of immune responses,&#xD;
      especially those related to type-1 T helper cell activity, may contribute to better efficacy&#xD;
      in combining ribavirin with IFN-alpha for treatment of chronic hepatitis C. The aim of the&#xD;
      present study is to evaluate the efficacy and safety of a triple regimen, a combination&#xD;
      treatment with Interferon gamma, Interferon alfa-2b plus Ribavirin in patients who have not&#xD;
      previously responded to interferon alpha in combination of ribavirin.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Genotype 3</condition>
  <condition>Non-responders</condition>
  <condition>Relapsers</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interferon alpha, ribavirin, interferon gamma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Interferon alpha, ribavirin, amantadine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>interferon alpha-2b, ribavirin, interferon-gamma,</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>interferon alpha-2b, ribavirin, amantadine</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Non-responders and relapsers to previous interferon and ribavirin therapy given for&#xD;
             six months&#xD;
&#xD;
          -  HCV genotype 3&#xD;
&#xD;
          -  Compensated liver disease&#xD;
&#xD;
          -  Hb ≥10 g/dl (females),≥11 g/dl (males)&#xD;
&#xD;
          -  Platelets count ≥ 100,000 / cubic mm&#xD;
&#xD;
          -  Neutrophils count ≥1,500/cubic mm&#xD;
&#xD;
          -  ≥18 years to ≤ 70 years.&#xD;
&#xD;
          -  At least one abnormal ALT value in the last year.&#xD;
&#xD;
          -  TSH level within normal limits.&#xD;
&#xD;
          -  Non pregnant adult females.&#xD;
&#xD;
          -  Absence of drug or alcohol abuse.&#xD;
&#xD;
          -  Informed consent given by the patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient younger than 18 yrs and older than 70 yrs.&#xD;
&#xD;
          -  Hepatitis B or HIV co-infection.&#xD;
&#xD;
          -  Severe renal dysfunction or creatinine clearance less than 50 ml/min&#xD;
&#xD;
          -  Pregnant women or breast feeding women.&#xD;
&#xD;
          -  Suspected hypersensitivity to Interferon alpha, gamma or ribavirin.&#xD;
&#xD;
          -  Decompensated liver cirrhosis.&#xD;
&#xD;
          -  History or any other evidence of other causes of CLD other than hepatitis C infection&#xD;
             ( like hemochromatosis,, autoimmune hepatitis, metabolic liver disease, alcoholic&#xD;
             liver disease, toxin exposure, Wilson's disease,Drug induced liver disease)&#xD;
&#xD;
          -  Active malignant disease.&#xD;
&#xD;
          -  Any known pre-existing medical condition that could interfere with subject's&#xD;
             participation or completion of study such as psychiatric condition, seizures disorder&#xD;
             requiring medications, co existing heart diseases, lung diseases, poorly controlled&#xD;
             diabetes, auto immune diseases, gout)&#xD;
&#xD;
          -  History of interferon and/or ribavirin intolerance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zaigham Abbas, FCPS, FACG</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Aga Khan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medicare Clinic</name>
      <address>
        <city>Karachi</city>
        <zip>74800</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Aga Khan University Hospital</name>
      <address>
        <city>Karachi</city>
        <zip>74800</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <study_first_submitted>October 2, 2007</study_first_submitted>
  <study_first_submitted_qc>October 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2007</study_first_posted>
  <last_update_submitted>October 26, 2010</last_update_submitted>
  <last_update_submitted_qc>October 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2010</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Interferon-gamma</mesh_term>
    <mesh_term>Amantadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

